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Abstract
Background: Breast cancer is the most common cause of cancer death in the western world. The
expression differences of many proteins are associated with breast cancer progression or
suppression. The purpose of the study was to determine the expression of nm23 protein in the
invasion status and metastatic potential of breast cancer by using tissue microarray and to
determine its role in breast cancer based on the expression of nm23 gene product.
Method: nm23 protein expression was examined by immunohistochemistry (IHC) using
commercially available tissue microarray containing malignant and normal breast tissues from 216
patients.
Results: a similar percentage of cases showed positive cytoplasmic/nuclear staining for nm23 in
normal breast tissue (85.7%), primary breast carcinoma node negative (97.5%) and carcinoma with
lymph node metastasis (92.1%). Nuclear localization of staining for nm23 protein was higher in
infiltrating ductal carcinoma (IDC) node positive (24.3%) and in matched lymph mode metastasis
(18.9%) compared to IDC node negative (4.9%). Strong intensity of cytoplasmic/nucleus staining
was observed in IDC node negative (42.6%), in IDC node positive (57.1%), and Infiltrating lobular
carcinoma (ILC) node negative (44%) compared to normal breast tissue (16.7%).
Conclusion: nm23 protein expression appears widely expressed in normal breast, early and
advanced breast cancer stages. Interestingly our study found that strong staining intensity and
nuclear localization of nm23 protein may prove to be a useful marker of breast cancer progression.
Introduction
Cancer is characterized by uncontrolled growth (prolifer-
ation) of cells [1-3] and their ability to invade other
organs or tissues, either by invasion or metastasis [2-4].
Although there are many types of cancer, all begin with
uncontrolled growth of abnormal single cells in the body
[3]. Breast cancer is the most common malignant neo-
plasm in women. Breast cancer is the commonest cancer
among women in United Kingdom [5]. Breast cancer
comprised 30.4 % of all female cancers in Malaysia in
2002 [6]. Approximately 182,000 estimated new cases of
women with breast cancer are seen in the United States
each year [7,8]. The number of women who die of breast
cancer is approximately 46,000 each year in USA [7]. One
out of eight women in United States and out of ten
women in Europe is at risk of developing breast cancer at
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with breast cancer arise not as a result of primary tumor
but from its metastatic spread to distant sites in the body
[10,11]. Once spread and secondary masses are formed,
breast cancers are usually incurable [12]. Approximately
one-third of the node negative breast cancer patients
develop metastatic disease, whereas the other two-thirds
do not develop metastasis despite not receiving chemo-
therapy [13]. Breast cancer is considered to be a systemic
disease as most breast carcinoma metastasizes before
diagnosis of the primary lesion [14]. Therefore, early
detection of metastasized lesion and identification of
more effective therapeutic modalities for metastatic dis-
ease are necessary if the prognosis for patients with
advanced breast cancer is to improve. nm23 gene located
on chromosome 17 q21.3 (A subunit by nm23-H1 and B
subunit by nm23-H2) encodes nucleoside diphosphate
kinase. It has been reported that differential regulation of
nm23 by p53 in different cell types is an important com-
ponent in the molecular mechanisms of tumor metastasis
[15,16]. Other study reported that high nm23 expression
is associated with older age (> 35 years) and smaller
tumor size [17]. Also high nm23 expression is associated
with the absence of distant metastasis [18]. Low expres-
sion is predictive of distant metastasis and appears to be a
risk factor that is independent of the presence or absence
of positive axillary nodes at diagnosis [18]. In contrast,
several studies of lung and pancreatic carcinoma reported
that nm23 expression correlated with advanced tumours
[19-22]. Thus, the putative usefulness of nm23 in predic-
tion of the clinical course of breast cancer patients
remains to be identified. The main purpose of the study
was to find the expression pattern of nm23 proteins in dif-
ferent types of breast cancer with or without lymph node
involvement and to determine its role in breast cancer
using tissue microarray.
Materials and methods
Formalin-fixed paraffin-embedded tissue microarrays
from 188 lymph node negative breast cancer patients, 50
breast cancer patients with lymph node metastasis (50
malignant tissues and 50 matched lymph node tissue
cores with metastasis) and 8 normal breast tissue cores
were analyzed by immunohistochemistry for the expres-
sion nm23 protein. Included in this study were patients
with infiltrating ductal carcinoma, infiltrating lobular car-
cinoma, normal breast tissue and lymph node metastasis.
The final number was 122 tissue cores of node negative
infiltrating ductal carcinoma, 41 node negative infiltrat-
ing lobular carcinoma, seven normal breast tissue, 40
node positive (38 infiltrating ductal carcinoma, 2 infiltrat-
ing lobular carcinoma) and 46 tissue cores of lymph node
metastasis. We did not evaluate infiltrating lobular carci-
noma node positive because of the low sample size (2
cases). Forty six 3 tissue cores were excluded from statistics
because very little cancer cells or no breast cancer tissue
were seen. The total number after exclusion was 254 tissue
cores (37 matched tissues) of 216 patients.
Immunohistochemistry (IHC)
In principle, rabbit Anti-Human polyclonal primary anti-
body against nm23 protein (Code No. A0096, from
DakoCytomation, Denmark) was used on deparaffinized
tissue microarray slides (Cat. No. BR 2001, BR 1001 from
Biomax, USA). A secondary detection system (DAKO
Envision) enhanced with conjugated polymer was used to
bind with the primary antibody. DAB chromogen was
used for permanent color development and detection
under microscope.
The percentage of carcinoma cells with cytoplasmic/mem-
branous/nuclear staining was recorded on each specimen
at 200× magnification, using light microscope. The
expression of nm23 was scored in all tumors as positive or
negative. Positive: ≥ 75% stained cells. Negative: no cells
were stained. Also the intensity of staining was catego-
rized into three groups: weak, moderate and strong. This
was ascertained by a single qualified pathologist.
A tissue section of normal breast was used as positive con-
trol for nm23. Rabbit IgG isotype (Sigma- Aldrich, USA)
was used instead of primary antibody in the immunohis-
tochemical technique on a tissue section each of breast
cancer and normal breast as negative control (Figure 1).
Negative control, nm23 protein immunohistochmical staining in normal breast tissue, sh wi g abse t staining (×200)Figu e 1
Negative control, nm23 protein immunohistochmical staining 
in normal breast tissue, showing absent staining (×200).Page 2 of 6
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60°C for 30 minutes. The slides were immersed in two
changes of xylene (10 minutes for each) to remove paraf-
fin. Slides were then immersed in 3 different concentra-
tions of ethanol 100%, 95%, 70% ethanol for 5 minutes
each. Slides were rinsed with distilled water to remove
ethanol and left for 5 minutes. The slides were then placed
in target retrieval solution EDTA buffer pH 9.0 (DAKO)
and heated on microwave for 20 minutes at maximum
setting. Slides were allowed to cool at room temperature
and rinsed with Tris Buffered saline (TBS) mixed with
tween 20 (2 changes). Slides were covered with peroxidase
blocking solution (DAKO) and left for 15 minutes, fol-
lowed by rinsing with TBS buffer mixed with tween 20 (2
changes). Then 200 μl of primary antibody (dilution
1:25) was added on the tissue microarray slides and left
for 60 minutes, followed by rinsing with TBS mixed with
tween 20 (three changes one minute each change). Two
drops of DAKO Envision/HRP, Rabbit/Mouse (secondary
antibody) were added on the slides and left for 30 min-
utes, followed by rinsing with TBS mixed with tween 20
(Three changes, one minute each change). After that DAB
substrate (DAKO) was added on section slides and left for
10 minutes (40 μl DAB concentrate, 2 ml substrate
buffer), followed by rinsing, immersion into hematoxylin
and 4 different concentrations of ethanol 70%, 80%, 95%
and 100% for 2 minutes each. After that slides were
immersed in two changes of xylene (2 minutes each) and
cover slipped. All incubation steps after heat induced
epitope retrieval were carried at room temperature.
Results
A majority of positive cases (i.e., ≥ 75 % stained cells)
showed cytoplasmic stained cells with nm23 protein. The
immunohistochemical expression of nm23 protein was
observed in 97.5% (119/122) of node negative infiltrating
ductal carcinoma (IDC). Strong intensity of staining was
observed in 42.6% (52/122) and moderate intensity in
35.2% (43/122).
Positive expression of nm23 was observed in 61% (25/
41) of node negative infiltrating lobular carcinoma (ILC).
The strong staining intensity were observed in 44% (11/
25) while moderate staining in 16% (4/25). The expres-
sion of nm23 protein in normal breast tissues was seen in
85.7% (6/7) cases. Weak staining intensity was observed
in 66.7% (4/6) and strong staining in 16.7% (1/6). Differ-
ent staining intensity had been found in (2/2) tissue cores
containing infiltrating lobular carcinoma (strong staining
intensity) and normal adjacent breast tissue (weak stain-
ing intensity) (figure 2, figure 3).
The staining of nm23 in node positive infiltrating ductal
carcinoma (IDC) was observed in 92.1 % (35/38) with
strong staining intensity noted in 57.1% (20/35) cases.
The expression of nm23 protein was observed in 89.2%
(41/46) of metastatic infiltrating ductal carcinoma (IDC
with lymph node metastasis) with strong staining inten-
sity noted in 31.7 % (13/41) cases.
It was observed that 89.2% (33/37) of the cases showed
positive expression of nm23 protein in both infiltrating
Strong staining intensity of nm23 protein within infiltrating lobular c rc oma while weak staining intensity within adja-cent normal breast tissue (×200)Fig re 3
Strong staining intensity of nm23 protein within infiltrating 
lobular carcinoma while weak staining intensity within adja-
cent normal breast tissue (×200).
Strong staining intensity of nm23 protein within infiltrating lobular carc oma wh le absent within adjacent ormal breast tiss e (×200)Fig re 2
Strong staining intensity of nm23 protein within infiltrating 
lobular carcinoma while absent within adjacent normal breast 
tissue (×200).Page 3 of 6
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metastasis. Two of 37 cases (5.4%) showed negative
expression of nm23 in both sites of infiltrating ductal car-
cinoma and its matched lymph node metastasis. One case
showed positive expression of nm23 at the site of infiltrat-
ing ductal carcinoma and negative nm23 expression in its
matched lymph node metastasis. Also one case showed
negative expression of nm23 infiltrating ductal carcinoma
with positive nm23 expression in its matched lymph node
metastasis (Table 1).
Both nuclear and cytoplasmic staining was seen in 6/122
(4.9%) of node negative IDC cases, 2/41 (4.8%) of node
negative ILC cases, 9/37 (24.3%) of node positive IDC
cases and 7/37 (18.9%) (Figure 4) in the matched lymph
node metastasis cases (Table 2). Nuclear staining was not
seen in normal breast
Discussion
nm23 protein was originally identified as a metastasis
suppressor protein [23] and many previous studies
reported reduced expression of nm23 protein correlated
with metastasis or reduced survival for patients with
breast cancer [24-29]. Recurrences of breast cancer were
accompanied by nm23-loss [30]. In contrast, several stud-
ies of lung and pancreatic carcinoma reported that nm23
expression correlated with an advanced tumor [19-22].
Also several breast carcinoma studies have shown that low
nm23 expression correlates with poor prognosis [31-33]
but the dynamics of its expression pattern and compart-
mentalization in breast cancer remains poorly under-
stood.
nm23 was expressed in normal breast tissue as well as in
node negative IDC breast cancer, node negative ILC breast
cancer, node positive IDC breast cancer, and matched
lymph node metastasis in 85.7%, 97.5%, 61%, 92.1%,
and 89.2% cases respectively. Among 97.5% node nega-
tive IDC cases, 42.6% had strong staining intensity and
only 19.7 % had a weak staining. nm23 was expressed in
61% of node negative ILC cases indicating that nm23 pro-
tein expression was associated more with infiltrating node
negative ductal carcinoma than node negative infiltrating
lobular carcinoma. As expected, ILC has been reported to
be more aggressive in nature compared to IDC. Expression
of nm23 protein was observed in normal breast tissues in
85.7% of cases with strong staining intensity observed in
only 16.7% cases. In two tissue cores it was clear that nor-
mal breast had much weaker or negative staining com-
pared to adjacent lobular cancer cells. These results
suggest nm23 expression increases in intensity in breast
cancer compared to normal breast. Usually normal breast
tissue expresses nm23 at baseline level in contrast to the
strong expression which may reflect abnormal accumula-
tion of nm23 (may be the altered form which is function-
ally inactive but resistant to degradation) in the early
phases of cancer genesis.
In this study we observed a similar percentage of cases
with positive staining for nm23 in normal breast tissue,
node negative IDC as well as with lymph node metastasis
with notable exception ILC. This suggests a relationship
between a down regulation of nm23 expression and ILC.
It may be possible that, other pathways are involved in
progression of metastatic IDC.
Table 2: Positive nuclear staining of nm23 in IDC, ILC node 
negative and positive
Site Positive Nuclear staining n (%)
IDC node negative 6 122 (4.9 %)
ILC node negative 2 41 (4.8 %)
IDC node positive 9 37 (24.3 %)
Matched Lymph node 7 37 (18.9 %)
nm23 protein immunohistochmical staining in infiltrating duc-tal carcinoma, showing Str ng nuc ear and cytoplasmic stain-ing (×200)Fi u e 4
nm23 protein immunohistochmical staining in infiltrating duc-
tal carcinoma, showing Strong nuclear and cytoplasmic stain-
ing (×200).
Table 1: The staining of nm23 in IDC and its lymph node 
metastasis for 37 patients
Staining Primary site IDC Matched lymph node
Both Positive 33(89.2 %)
Both negative 2 (5.4 %)
positive IDC only 1 (2.7 %) 0
positive Lymph node only 0 1 (2.7 %)
Total 37 (100%)Page 4 of 6
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staining was observed in cancer cells in 6/122 (4.9%) of
IDC node negative cases, 2/41 (4.8%) of ILC node nega-
tive cases, 9/37 (24.3%) of IDC node positive cases and 7/
37 (18.9%) in matched lymph node metastasis cases.
These results indicate that nuclear localization of nm23
protein is seen more frequently in node positive meta-
static cases compared with IDC or ILC node negative
cases, suggesting that abnormal nuclear accumulation of
nm23 may provide an indication of tumor progression.
We cannot be sure whether this nuclear accumulation is
due to altered (mutated or truncated form) nm23 with
different half-life as up-regulation of nm23 expression is
unusual in at least metastatic carcinoma considering its
role as tumor suppressor. However, this requires to be
proven.
Conclusion
In conclusion nm23 protein expression appears expressed
widely in normal breast, early and advanced stages of
breast cancer, predominantly in ductal carcinoma. It sug-
gests a less significance of nm23 induced pathway of
tumor suppression. While, in addition, abnormal cyto-
plasmic and nuclear localization of this protein in node
positive and metastatic cases suggest a possible role of
altered nm23 which is functionally inactive with longer
half-life. However, this study indicates a complex role of
nm23 in breast cancer of different types and in metastatic
stages and may not solely function as tumor suppressor as
commonly perceive. A larger study with more ILC and
metastatic cases may clarify the role and function of nm23
in breast cancer.
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